Alumis Inc’s recently made public that its Director Tananbaum James B. acquired Company’s shares for reported $0.12 million on May 02 ’25. In the deal valued at $4.62 per share,25,000 shares were bought. As a result of this transaction, Tananbaum James B. now holds 4,227,670 shares worth roughly $13.27 million.
Then, Tananbaum James B. bought 20,000 shares, generating $86,800 in total proceeds. Upon buying the shares at $4.34, the Director now owns 4,247,670 shares.
Before that, Foresite Labs, LLC bought 25,000 shares. Alumis Inc shares valued at $115,500 were divested by the 10% Owner at a price of $4.62 per share. As a result of the transaction, Foresite Labs, LLC now holds 4,227,670 shares, worth roughly $13.27 million.
A number of analysts have revised their coverage, including Oppenheimer’s analysts, who began to cover the stock in late January with a ‘”an Outperform”‘ rating. Robert W. Baird began covering ALMS with “an Outperform” recommendation on October 31, 2024. H.C. Wainwright started covering the stock on October 17, 2024. It rated ALMS as “a Buy”.
Price Performance Review of ALMS
On Friday, Alumis Inc [NASDAQ:ALMS] saw its stock fall -1.26% to $3.14. Over the last five days, the stock has lost -12.53%. Alumis Inc shares have fallen nearly -60.05% since the year began.
Levels Of Support And Resistance For ALMS Stock
The 24-hour chart illustrates a support level at 3.07, which if violated will result in even more drops to 3.00. On the upside, there is a resistance level at 3.24. A further resistance level may holdings at 3.34.
How much short interest is there in Alumis Inc?
A steep rise in short interest was recorded in Alumis Inc stocks on 2025-05-30, growing by 0.15 million shares to a total of 3.69 million shares. Yahoo Finance data shows the prior-month short interest on 2025-04-30 was 3.53 million shares. There was a rise of 4.13%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on July 23, 2024 when Morgan Stanley began covering the stock and recommended ‘”an Overweight”‘ rating along with a $36 price target.
